Study of D3L-002 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has spread or cannot be removed and has progressed after at least one prior treatment or has no standard therapy available.
- You are 18 years or older.
- You are able to do daily activities with minimal help (ECOG 0-1).
- Your organs (blood, liver, kidneys) are working well enough.
- You have not had prior treatment with drugs targeting TIGIT or PVRIG pathways.
- You do not have active or serious health issues like lung disease, autoimmune disease, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for people with advanced solid tumors that have HER2 changes. The goal is to see if it can shrink tumors or slow growth.
This early-stage trial tests a new drug called IDP-001 in people with advanced cancers that have spread or cannot be surgically removed. The study aims to find the right dose and see how well the drug works against various solid tumors.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
This Phase 1 trial tests D3L-001 alone in people with HER2-positive advanced solid tumors. It’s mainly looking to see how the drug works and how safe it is in this group.
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.